Pacira Pharmaceuticals Inc. (PCRX)

40.04
NASDAQ : Health Technology
Prev Close 38.73
Day Low/High 38.61 / 40.32
52 Wk Low/High 26.95 / 55.00
Avg Volume 510.70K
Exchange NASDAQ
Shares Outstanding 41.11M
Market Cap 1.59B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results For Controlling Postsurgical Pain In Dogs

Animal Health Partner, Aratana Therapeutics, Announces Positive Pivotal Results For Controlling Postsurgical Pain In Dogs

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) announced today that Aratana Therapeutics, Inc.

Pacira Pharmaceuticals Announces Timing For Second Quarter 2015 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals Announces Timing For Second Quarter 2015 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company's second quarter ended June 30, 2015 will be released before the market opens on Thursday, July 30, 2015.

Pacira Pharmaceuticals Appoints Scott Braunstein, MD, To Oversee Strategy And Corporate Development

Pacira Pharmaceuticals Appoints Scott Braunstein, MD, To Oversee Strategy And Corporate Development

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the appointment of Scott Braunstein, MD, to the newly created position of senior vice president, strategy and corporate development.

PCRX: Insiders vs. Shorts

PCRX: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 05/15/2015 settlement date, and Pacira Pharmaceuticals Inc. is one of the most shorted stocks of the Russell 3000, based on 6.77 "days to cover" versus the median component at 5.60.

Short Interest In Pacira Pharmaceuticals Surges 66.3%

Short Interest In Pacira Pharmaceuticals Surges 66.3%

The most recent short interest data has been released by the NASDAQ for the 05/15/2015 settlement date, which shows a 3,047,170 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 7,645,824, an increase of 66.26% since 04/30/2015.

Pacira Pharmaceuticals Announces Completion Of End-of-Review Process With FDA Regarding EXPAREL SNDA For Nerve Block

Pacira Pharmaceuticals Announces Completion Of End-of-Review Process With FDA Regarding EXPAREL SNDA For Nerve Block

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it completed an End-of-Review process with the U.

Pacira Pharmaceuticals, Inc. To Present At Investor Conferences In June

Pacira Pharmaceuticals, Inc. To Present At Investor Conferences In June

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present an overview of the company at the...

Pacira Announces New Data Supporting Clinical And Pharmacoeconomic Utility Of EXPAREL In Patients Undergoing Various Surgical Procedures

Pacira Announces New Data Supporting Clinical And Pharmacoeconomic Utility Of EXPAREL In Patients Undergoing Various Surgical Procedures

Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) today announced data from three studies evaluating the clinical and pharmacoeconomic utility of EXPAREL ® (bupivacaine liposome injectable suspension) for postsurgical pain...

Pacira Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference

Pacira Pharmaceuticals, Inc. To Present At The Bank Of America Merrill Lynch 2015 Health Care Conference

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch...

Market News: Apple Inc, Yelp Inc, Pacira Pharmaceuticals

Market News: Apple Inc, Yelp Inc, Pacira Pharmaceuticals

The stock markets in the United States suffered another decline primarily due to the selloff in small caps and biotechnology companies. Sign up for our free newsletter Commenting on the market trends,...

Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues Of $56.0 Million And First Quarter 2015 Financial Results

Pacira Pharmaceuticals, Inc. Reports First Quarter EXPAREL Revenues Of $56.0 Million And First Quarter 2015 Financial Results

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for...

Pacira Pharmaceuticals (PCRX) Stock Declines Today Following DOJ Subpoena

Pacira Pharmaceuticals (PCRX) Stock Declines Today Following DOJ Subpoena

Pacira Pharmaceuticals (PCRX) shares are falling after the Justice Department subpoenaed documents from the company concerning the advertisement for its Exparel pain reliever.

Pacira Receives Subpoena From The U.S. Department Of Justice

Pacira Receives Subpoena From The U.S. Department Of Justice

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it received a subpoena from the U.

Pacira Pharmaceuticals Announces Timing For First Quarter 2015 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals Announces Timing For First Quarter 2015 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company's first quarter ended March 31, 2015 will be released before the market opens on Thursday, April 30, 2015.

Pacira Announces New Data On Health Economic Benefits Of EXPAREL For Postsurgical Pain Control Following Total Knee Replacement Surgery

Pacira Announces New Data On Health Economic Benefits Of EXPAREL For Postsurgical Pain Control Following Total Knee Replacement Surgery

Pacira Pharmaceuticals Inc. (NASDAQ: PCRX) today announced results of new data from the University of Illinois College of Medicine analyzing the impact of EXPAREL® (bupivacaine liposome injectable suspension) used to...

Pacira Announces Data Reinforcing Benefits Of EXPAREL® For Postsurgical Pain Control Following Total Hip And Knee Replacement Surgery

Pacira Announces Data Reinforcing Benefits Of EXPAREL® For Postsurgical Pain Control Following Total Hip And Knee Replacement Surgery

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data demonstrating the benefits associated with the use of EXPAREL ® (bupivacaine liposome injectable suspension) in a study of over 2,200 hip and knee...

New Data Demonstrate Reduced Opioid Requirements Following Use Of EXPAREL In Hysterectomy And Mastectomy Procedures

New Data Demonstrate Reduced Opioid Requirements Following Use Of EXPAREL In Hysterectomy And Mastectomy Procedures

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced results of two data presentations on the impact of EXPAREL ® (bupivacaine liposome injectable suspension) on postsurgical opioid requirements in...

Pacira Pharmaceuticals, Inc. To Present At The Barclays Global Healthcare Conference

Pacira Pharmaceuticals, Inc. To Present At The Barclays Global Healthcare Conference

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Barclays Global Healthcare Conference...

PCRX: Insiders vs. Shorts

PCRX: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 02/13/2015 settlement date, and Pacira Pharmaceuticals Inc. is one of the most shorted stocks of the Russell 3000, based on 9.25 "days to cover" versus the median component at 5.17.

Pacira Pharmaceuticals (PCRX): Today's Weak On High Volume Stock

Pacira Pharmaceuticals (PCRX): Today's Weak On High Volume Stock

Trade-Ideas LLC identified Pacira Pharmaceuticals (PCRX) as a weak on high relative volume candidate

Notable Two Hundred Day Moving Average Cross - PCRX

Notable Two Hundred Day Moving Average Cross - PCRX

In trading on Monday, shares of Pacira Pharmaceuticals Inc. crossed below their 200 day moving average of $95.51, changing hands as low as $92.29 per share.

Pacira Receives Complete Response Letter From FDA For SNDA Seeking Approval Of EXPAREL® Use In Nerve Block To Provide Postsurgical Analgesia

Pacira Receives Complete Response Letter From FDA For SNDA Seeking Approval Of EXPAREL® Use In Nerve Block To Provide Postsurgical Analgesia

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Complete Response Letter (CRL) from the U.

Pacira Pharmaceuticals (PCRX) Upgraded From Sell to Hold

Pacira Pharmaceuticals (PCRX) Upgraded From Sell to Hold

Pacira Pharmaceuticals (PCRX) has been upgraded by TheStreet Ratings from Sell to Hold with a ratings score of C-.

Analysts' Actions: American Express, Cablevision, State Street, T-Mobile and More

Analysts' Actions: American Express, Cablevision, State Street, T-Mobile and More

Here are today's top research calls.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ASTE, CLGX, DKL, PCRX Downgrades: ATAI, BAK, BEE, FELE, INOD, QEP, RAS, RLGY, SUI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Pacira Pharmaceuticals, Inc. Reports 2014 Financial Results

Pacira Pharmaceuticals, Inc. Reports 2014 Financial Results

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated...

Pacira Pharmaceuticals, Inc. Announces Resolution Of Warning Letter With FDA's Office Of Prescription Drug Promotion

Pacira Pharmaceuticals, Inc. Announces Resolution Of Warning Letter With FDA's Office Of Prescription Drug Promotion

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced resolution of matters pertaining to certain promotional aspects of EXPAREL detailed in a recent Warning Letter from the U.

Pacira Pharmaceuticals Announces Timing For 2014 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals Announces Timing For 2014 Financial Results Webcast And Conference Call

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company's fourth quarter and year ended December 31, 2014, will be released before the market opens on Tuesday, February 24,...

Pacira Pharmaceuticals, Inc. To Host Analyst & Investor Day On Jan. 22 In New York

Pacira Pharmaceuticals, Inc. To Host Analyst & Investor Day On Jan. 22 In New York

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that it has scheduled an Analyst & Investor Day on Thursday, Jan.

Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue Of $61.8 Million And Estimated Full-Year Total Revenue Of $197.7 Million

Pacira Pharmaceuticals, Inc. Reports Estimated Fourth Quarter Total Revenue Of $61.8 Million And Estimated Full-Year Total Revenue Of $197.7 Million

Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided its unaudited EXPAREL® and total revenue estimates for the fourth quarter and full-year 2014.

TheStreet Quant Rating: C- (Hold)